Switching off T cells before they begin to damage the nervous system is the basis of an Australian therapy for multiple sclerosis (MS), which is expected to begin clinical trials by the end of 2017.

Developed by researchers at Victoria University in western Melbourne and the University of Patras in Greece, it brings together peptides, or protein fragments, with a biochemical delivery system already shown to be effective in cancer vaccine clinical trials. Continue reading Turning off toxic T cells in MS clinical trial →